คำอธิบาย
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
กลไก
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
ความสำคัญทางคลินิก
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
การจัดการ
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.